When did MaxCyte report Q2 2025 earnings?

MaxCyte (MXCT) reported Q2 2025 earnings on August 6, 2025 after market close.

What were MaxCyte's Q2 2025 revenue and EPS?

MaxCyte reported revenue of $8.5M and diluted EPS of $-0.12 for Q2 2025.

Did MaxCyte beat estimates in Q2 2025?

Revenue missed the consensus estimate of $10.4M by $1.9M. EPS missed the consensus estimate of $-0.10 by $0.02.

How did MaxCyte's Q2 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue declined 18.4% from $10.4M a year earlier and diluted EPS declined 33.3% from $-0.09.

Where can I find MaxCyte's Q2 2025 SEC filings?

You can read the 10-Q periodic report (0001558370-25-010554) directly on SEC EDGAR. The filing index links above go to sec.gov.

MaxCyte MXCT Q2 2025 earnings

Reported August 6, 2025 · After market close

Revenue$8.5MMiss by $1.9M Diluted EPS-$0.12Miss by $0.02

Revenue estimate$10.4M

EPS estimate-$0.10

Next report

Aug 12, 2026 (in a month)

Revenue estimate$6.6M

EPS estimate-$0.12

Financials

Q2 2025

Income statement

See full

Revenue$8.5M-18.4%

Gross profit$7.0M-21.8%

Operating income-$14.2M-18.9%

Net income-$12.4M-31.8%

EPS (diluted)-$0.12-33.3%

Balance sheet

See full

Cash & equivalents$15.2M-59.4%

Total debt$18.5M-0.1%

Total equity$190.7M-13.8%

Total assets$219.8M-12.6%

Cash flow

See full

Operating cash flow-$9.9M-104%

CapEx$584.0K+98.6%

Free cash flow-$10.4M-104%

Valuation & ratios

Valuation

as of 06/30/25

See full

Market cap$235.5M-42.3%

Enterprise value$238.78M-38.6%

P/S6.6×-2.4×

Profitability

See full

Gross margin79.8%-8.6pp

Operating margin-149.6%+132pp

Net margin-125.2%+193pp

FCF margin-107%+1,090pp

Returns & leverage

See full

Return on equity-21.7%+15.6pp

Debt / equity0.1×0.0×

Current ratio12.4×-1.9×

Segments

By product

See full

License$2.9M—

Assay And Other Service Revenue$310.0K—

By segment

See full

Cell Engineering Technology$8.5M-18.4%

Versus estimates

Revenue

Q1 2026$9.7MBeat by $2.4M Q4 2025$7.3MMiss by $1.8M Q3 2025$6.8MMiss by $2.6M

Q2 2025$8.5MMiss by $1.9M

Q1 2025$10.4MBeat by $821.8K Q4 2024$8.7MMiss by $578.7K

Diluted EPS

Q1 2026-$0.04Beat by $0.06 Q4 2025-$0.06Beat by $0.02 Q3 2025-$0.12Miss by $0.01

Q2 2025-$0.12Miss by $0.02

Q1 2025-$0.10In line Q4 2024-$0.10Beat by $0.02

Ask the moment MaxCyte reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did MaxCyte report Q2 2025 earnings?: MaxCyte (MXCT) reported Q2 2025 earnings on August 6, 2025 after market close.
What were MaxCyte's Q2 2025 revenue and EPS?: MaxCyte reported revenue of $8.5M and diluted EPS of $-0.12 for Q2 2025.
Did MaxCyte beat estimates in Q2 2025?: Revenue missed the consensus estimate of $10.4M by $1.9M. EPS missed the consensus estimate of $-0.10 by $0.02.
How did MaxCyte's Q2 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue declined 18.4% from $10.4M a year earlier and diluted EPS declined 33.3% from $-0.09.
Where can I find MaxCyte's Q2 2025 SEC filings?: You can read the 10-Q periodic report (0001558370-25-010554) directly on SEC EDGAR. The filing index links above go to sec.gov.